Subgroups and Heterogeneity in Cost-Effectiveness Analysis
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Net Health Benefits: A New Framework for the Analysis of Uncertainty in Cost-Effectiveness Analysis
Stinnett, A. A., & Mullahy, J. (1998) · Medical Decision Making · doi:10.1177/0272989x98018002s09 · Cited by 1,102
A consumer's guide to subgroup analyses
Oxman, A. D., & Guyatt, G. H. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-1-78 · Cited by 914
Claxton, K. (1999) · Journal of Health Economics · doi:10.1016/s0167-6296(98)00039-3 · Cited by 889
Testing for Qualitative Interactions between Treatment Effects and Patient Subsets
Gail, M., & Simon, R. (1985) · Biometrics · doi:10.2307/2530862 · Cited by 651
Mark, D. B., Hlatky, M. A., Califf, R. M., Naylor, C. D., Lee, K. L., Armstrong, P. W., Barbash, G., White, H., Simoons, M. L., Nelson, C. L., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322106 · Cited by 521
Carrier Screening for Cystic Fibrosis: Costs and Clinical Outcomes
Asch, D. A., Hershey, J. C., Dekay, M. L., Pauly, M. V., Patton, J. P., Jedrziewski, M. K., Frei, F., Giardine, R., Kant, J. A., & Mennuti, M. T. (1998) · Medical Decision Making · doi:10.1177/0272989x9801800209 · Cited by 375
Statistical assessment of the learning curves of health technologies
Ramsay, C. R., Grant, A. M., Wallace, S. A., Garthwaite, P. H., Monk, A. F., & Russell, I. T. (2001) · Health Technology Assessment · doi:10.3310/hta5120 · Cited by 353
Value based pricing for NHS drugs: an opportunity not to be missed?
Claxton, K., Briggs, A., Buxton, M. J., Culyer, A. J., McCabe, C., Walker, S., & Sculpher, M. J. (2008) · BMJ · doi:10.1136/bmj.39434.500185.25 · Cited by 230 · cited 1×
“Background cost).[1] This trade-off is assessed by comparing the”
MethodSelf-citationInvestigating underlying risk as a source of heterogeneity in meta-analysis
Thompson, S. G., Smith, T. C., & Sharp, S. J. (1997) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19971215)16:23<2741::aid-sim703>3.0.co;2-0 · Cited by 226
Culyer, A., McCabe, C., Briggs, A., Claxton, K., Buxton, M., Akehurst, R., Sculpher, M., & Brazier, J. (2007) · Journal of Health Services Research & Policy · doi:10.1258/135581907779497567 · Cited by 173 · cited 1×
“incremental cost per QALY gained against the costThe brief of the National Institute for Health and effectiveness threshold, which acts as a proxy for the Clinical Excellence (NICE) to consider the cost opportunity cost.[2] In other words, in assessing cost effectiveness, as well as the clinical effectiveness, of effe…”
MethodSelf-citation
Cited by
Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., et al. (2022) · Value in Health · doi:10.1016/j.jval.2021.10.008 · Cited by 847
Use of Indirect and Mixed Treatment Comparisons for Technology Assessment
Sutton, A., Ades, A. E., Cooper, N., & Abrams, K. (2008) · PharmacoEconomics · doi:10.2165/00019053-200826090-00006 · Cited by 355
Exploring Uncertainty in Cost-Effectiveness Analysis
Claxton, K. (2008) · PharmacoEconomics · doi:10.2165/00019053-200826090-00008 · Cited by 210
“However, NICE needs separate estimates of efThe choice of model structure and complexity is fects and costs for identifiable groups of patients always a trade-off between descriptive realism, with different characteristics.[5] If NICE requires computational burden and evidence requirements.”
BackgroundUncertainty and patient heterogeneity in medical decision models
Groot Koerkamp, B., Weinstein, M. C., Stijnen, T., Heijenbrok-Kal, M. H., & Hunink, M. G. M. (2010) · Medical Decision Making · doi:10.1177/0272989x09342277 · Cited by 105
“Criteria are being developed to decide when it is justified to model heterogeneity in a parameter.(54) Sensitivity analysis may evaluate the optimal strategy for various subgroups and involves repeated analysis of a model for, for example, different age groups.”
BackgroundKazi, D. S., Abdullah, A. R., Arnold, S. V., Basu, A., Bellows, B. K., Breathett, K., Chew, D. S., Cohen, D. J., DeJong, C., Heidenreich, P. A., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.05.009 · Cited by 14
Metadata
- Authors
- Sculpher, M.
- Venue
- PharmacoEconomics
- Published
- 2008
- Volume
- 26
- Issue
- 9
- Pages
- 799-806
- ISSN
- 1170-7690 (ISSN-L)
- OpenAlex
- W2080250864
- Cited by
- 168
- References
- 17
- FWCI
- 21.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subgroups and Heterogeneity in Cost-Effectiveness Analysis. https://app.cochat.ai/papers/10.2165/00019053-200826090-00009
- The paper
- Sculpher, M. (2008). Subgroups and Heterogeneity in Cost-Effectiveness Analysis. PharmacoEconomics. https://doi.org/10.2165/00019053-200826090-00009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.